Recent News

• 03.26.2026 - CORRESP - Correspondence
• 03.11.2026 - GT Biopharma to Participate in the 38th Annual Roth Conference
• 03.06.2026 - 10-Q/A - Quarterly report [Sections 13 or 15(d)]
• 03.06.2026 - 10-Q/A - Quarterly report [Sections 13 or 15(d)]
• 03.02.2026 - 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.02.2026 - 8-K - Current report
• 03.02.2026 - GT Biopharma Reports Full Year 2025 Financial Results
• 02.17.2026 - GT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference
• 02.03.2026 - GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3
• 02.02.2026 - EFFECT - Notice of Effectiveness

Recent Filings

• 03.06.2026 - 10-Q/A Quarterly report [Sections 13 or 15(d)]
• 03.06.2026 - 10-Q/A Quarterly report [Sections 13 or 15(d)]
• 03.02.2026 - 8-K Current report
• 03.02.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 01.30.2026 - EFFECT Notice of Effectiveness
• 01.30.2026 - 424B3 Prospectus [Rule 424(b)(3)]
• 01.21.2026 - S-1 General form for registration of securities under the Securities Act of 1933